Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD in Newly Diagnosed iMCD
NCT03982771Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in idiopathic multicentric Castleman disease (iMCD), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
bortezomib
03
Conditions
idiopathic multicentric Castleman disease (iMCD)
Beyond the preview
Go deeper on NCT03982771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982771.